{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:48:19Z","timestamp":1791658099785,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":204,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.prdoa.2026.100488","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:54:38Z","timestamp":1785074078000},"page":"100488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term real-world effectiveness of carbidopa\/levodopa enteral suspension after 36\u00a0months of treatment initiation in advanced Parkinson's disease in the US: final results from the PROviDE study"],"prefix":"10.1016","volume":"15","author":[{"given":"Rajesh","family":"Pahwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna L.","family":"Kandukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie H.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavnit","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Aldred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2026.100488_bb0005","doi-asserted-by":"crossref","unstructured":"Chaudhuri KR;Azulay JP;Odin P;Lindvall S;Domingos J;Alobaidi A;Kandukuri PL;Chaudhari VS;Parra JC;Yamazaki T;Oddsdottir J;Wright J;Martinez-Martin P. Economic burden of Parkinson's disease: a multinational, real-world, cost-of-illness study. Drugs Real World Outcomes 2024;11(1):1\u201311.","DOI":"10.1007\/s40801-023-00410-1"},{"issue":"6","key":"10.1016\/j.prdoa.2026.100488_bb0010","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1007\/s12325-021-01747-1","article-title":"The long-term impact of levodopa\/carbidopa intestinal gel on \u2018off\u2019-time in patients with advanced Parkinson\u2019s disease: a systematic review","volume":"38","author":"Antonini","year":"2021","journal-title":"Adv. Ther."},{"issue":"11","key":"10.1016\/j.prdoa.2026.100488_bb0015","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00702-024-02773-3","article-title":"Advanced therapies in Parkinson\u2019s disease: an individualized approach to their indication","volume":"131","author":"Schroter","year":"2024","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.prdoa.2026.100488_bb0020","author":"AbbVie Inc."},{"issue":"11","key":"10.1016\/j.prdoa.2026.100488_bb0025","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00702-023-02693-8","article-title":"Current and novel infusion therapies for patients with Parkinson\u2019s disease","volume":"130","author":"Antonini","year":"2023","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"5","key":"10.1016\/j.prdoa.2026.100488_bb0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3233\/JPD-225112","article-title":"Infusion therapies in the treatment of Parkinson\u2019s disease","volume":"13","author":"van Laar","year":"2023","journal-title":"J. Parkinsons Dis."},{"issue":"12","key":"10.1016\/j.prdoa.2026.100488_bb0035","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s40263-022-00963-9","article-title":"Comparative effectiveness of device-aided therapies on quality of life and off-time in advanced Parkinson\u2019s disease: a systematic review and Bayesian network meta-analysis","volume":"36","author":"Antonini","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.prdoa.2026.100488_bb0040","doi-asserted-by":"crossref","unstructured":"Olanow CW;Kieburtz K;Odin P;Espay AJ;Standaert DG;Fernandez HH;Vanagunas A;Othman AA;Widnell KL;Robieson WZ;Pritchett Y;Chatamra K;Benesh J;Lenz RA;Antonini A. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","DOI":"10.1016\/S1474-4422(13)70293-X"},{"issue":"5","key":"10.1016\/j.prdoa.2026.100488_bb0045","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3233\/JPD-225105","article-title":"Levodopa carbidopa intestinal gel in advanced Parkinson\u2019s disease: DUOGLOBE final 3-year results","volume":"13","author":"Chaudhuri","year":"2023","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100488_bb0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12883-019-1276-8","article-title":"Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients","volume":"19","author":"Fasano","year":"2019","journal-title":"BMC Neurol."},{"issue":"8","key":"10.1016\/j.prdoa.2026.100488_bb0055","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/mds.28595","article-title":"Intrajejunal infusion of levodopa\/carbidopa for advanced Parkinson\u2019s disease: a systematic review","volume":"36","author":"Tsunemi","year":"2021","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100488_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060547","article-title":"Combined and sequential treatment with deep brain stimulation and continuous intrajejunal levodopa infusion for Parkinson\u2019s disease","volume":"11","author":"van Poppelen","year":"2021","journal-title":"J. Pers. Med."},{"issue":"10","key":"10.1016\/j.prdoa.2026.100488_bb0065","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/acn3.50889","article-title":"Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson\u2019s disease patients with suboptimal response to deep brain stimulation","volume":"6","author":"Elkouzi","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"12","key":"10.1016\/j.prdoa.2026.100488_bb0070","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1002\/mds.23833","article-title":"Jejunal levodopa infusion in long-term DBS patients with Parkinson\u2019s disease","volume":"26","author":"Klostermann","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2026.100488_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of an abbreviated treatment satisfaction questionnaire for medication (TSQM-9) among patients on antihypertensive medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual. Life Outcomes"},{"issue":"1\u20132","key":"10.1016\/j.prdoa.2026.100488_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000455863","article-title":"Changes in quality of life in Parkinson\u2019s disease: how large must they be to be relevant?","volume":"48","author":"Horvath","year":"2017","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.prdoa.2026.100488_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-10-85","article-title":"Development and testing of a self administered version of the freezing of gait questionnaire","volume":"10","author":"Nilsson","year":"2010","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.prdoa.2026.100488_bb0090","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/mds.23476","article-title":"Parkinson\u2019s disease sleep scale--validation of the revised version PDSS-2","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100488_bb0095","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1212\/01.wnl.0000266669.18308.af","article-title":"Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure","volume":"69","author":"Katzenschlager","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.prdoa.2026.100488_bb0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/NNR.0000000000000162","article-title":"Psychometric evaluation of the patient-reported outcomes measurement information system fatigue-short form across diverse populations","volume":"65","author":"Ameringer","year":"2016","journal-title":"Nurs. Res."},{"key":"10.1016\/j.prdoa.2026.100488_bb0105","unstructured":"Antonini A;Poewe W;Chaudhuri KR;Jech R;Pickut B;Pirtosek Z;Szasz J;Valldeoriola F;Winkler C;Bergmann L;Yegin A;Onuk K;Barch D;Odin P;co-investigators Gs. Levodopa-carbidopa intestinal gel in advanced Parkinson's: final results of the GLORIA registry. Parkinsonism Relat. Disord. 2017;45:13\u201320."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100488_bb0110","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3233\/JPD-191605","article-title":"Levodopa-carbidopa intestinal gel monotherapy: GLORIA registry demographics, efficacy, and safety","volume":"9","author":"Poewe","year":"2019","journal-title":"J. Parkinsons Dis."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100488_bb0115","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","year":"2023","journal-title":"Neurol Ther."},{"key":"10.1016\/j.prdoa.2026.100488_bb0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/PPA.S24752","article-title":"A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence","volume":"6","author":"Barbosa","year":"2012","journal-title":"Patient Prefer. Adherence"},{"issue":"6","key":"10.1016\/j.prdoa.2026.100488_bb0125","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.27338","article-title":"Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease","volume":"33","author":"Fernandez","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2026.100488_bb0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2016.06.002","article-title":"Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson\u2019s disease: an open-label prospective observational study of effectiveness, tolerability and healthcare costs","volume":"29","author":"Palhagen","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100488_bb0135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ene.15558","article-title":"How resistant are levodopa-resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease","volume":"30","author":"Imbalzano","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.prdoa.2026.100488_bb0140","article-title":"Levodopa-carbidopa intestinal gel may improve treatment-resistant freezing of gait in Parkinson\u2019s disease","volume":"7","author":"Shackleford","year":"2022","journal-title":"Clin. Park. Relat. Disord."},{"issue":"9","key":"10.1016\/j.prdoa.2026.100488_bb0145","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00702-013-0981-5","article-title":"Motor and nonmotor complications in Parkinson\u2019s disease: an argument for continuous drug delivery?","volume":"120","author":"Chaudhuri","year":"2013","journal-title":"J. Neural Transm."},{"issue":"8","key":"10.1016\/j.prdoa.2026.100488_bb0150","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.parkreldis.2012.04.010","article-title":"Long-term 24-h levodopa\/carbidopa gel infusion in Parkinson\u2019s disease","volume":"18","author":"Busk","year":"2012","journal-title":"Parkinsonism Relat. Disord."}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259011252600068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259011252600068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:50:10Z","timestamp":1791654610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259011252600068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":30,"alternative-id":["S259011252600068X"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100488","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term real-world effectiveness of carbidopa\/levodopa enteral suspension after 36\u00a0months of treatment initiation in advanced Parkinson's disease in the US: final results from the PROviDE study","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100488"}}